Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Baert

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
BMC Health Services Research|December 23, 2025
Multi-stakeholder validation of an evidence-based core set of quality indicators for IBD in BelgiumLiselotte Fierens, Frank E Rademakers, Peter Bossuyt, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2025
Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control SubjectsKarlien Raymenants, Friedel Vulsteke, Tim Vanuytsel, et al.
Acta Clinica Belgica|January 27, 2021
Antimicrobial resistance of <i>Helicobacter pylori</i> in West Flanders - Belgium: an observational cross-sectional studyAlexander Vanden Bulcke, Bruno Waked, Lise Haems, et al.
European Journal of Gastroenterology & Hepatology|June 25, 2024
Development of a set of measurable outcome indicators for Flemish patients with inflammatory bowel diseaseLiselotte Fierens, Peter Bossuyt, Filip Baert, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 4, 2014
Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapyFilip Baert, David Drobne, Ann Gils, et al.
Clinical Chemistry and Laboratory Medicine|February 21, 2024
Analytical and diagnostic performance of Theradiag i-Tracker assays on IDS-iSYS for infliximab and adalimumab therapeutic drug monitoringPauline Herroelen, Hilde Vanpoucke, Filip Baert, et al.
Journal of Crohn'S & Colitis|March 2, 2019
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre StudyNiels Vande Casteele, Filip Baert, Sumin Bian, et al.
Gastroenterology|July 10, 2003
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort studySeverine Vermeire, Maja Noman, Gert Van Assche, et al.
Gut|April 12, 2015
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trialFilip Baert, Venkateswarlu Kondragunta, Steven Lockton, et al.
Journal of Crohn'S & Colitis|April 28, 2012
Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patientsFilip Baert, Elien Glorieus, Cathérine Reenaers, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
BMC Health Services Research|December 23, 2025
Multi-stakeholder validation of an evidence-based core set of quality indicators for IBD in BelgiumLiselotte Fierens, Frank E Rademakers, Peter Bossuyt, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2025
Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control SubjectsKarlien Raymenants, Friedel Vulsteke, Tim Vanuytsel, et al.
Acta Clinica Belgica|January 27, 2021
Antimicrobial resistance of <i>Helicobacter pylori</i> in West Flanders - Belgium: an observational cross-sectional studyAlexander Vanden Bulcke, Bruno Waked, Lise Haems, et al.
European Journal of Gastroenterology & Hepatology|June 25, 2024
Development of a set of measurable outcome indicators for Flemish patients with inflammatory bowel diseaseLiselotte Fierens, Peter Bossuyt, Filip Baert, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 4, 2014
Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapyFilip Baert, David Drobne, Ann Gils, et al.
Clinical Chemistry and Laboratory Medicine|February 21, 2024
Analytical and diagnostic performance of Theradiag i-Tracker assays on IDS-iSYS for infliximab and adalimumab therapeutic drug monitoringPauline Herroelen, Hilde Vanpoucke, Filip Baert, et al.
Journal of Crohn'S & Colitis|March 2, 2019
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre StudyNiels Vande Casteele, Filip Baert, Sumin Bian, et al.
Gastroenterology|July 10, 2003
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort studySeverine Vermeire, Maja Noman, Gert Van Assche, et al.
Gut|April 12, 2015
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trialFilip Baert, Venkateswarlu Kondragunta, Steven Lockton, et al.
Journal of Crohn'S & Colitis|April 28, 2012
Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patientsFilip Baert, Elien Glorieus, Cathérine Reenaers, et al.
Pageof 10